Soren Giese – General Manager, Amgen Italy
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen
Via Tazzoli, 6
20154 – Milano Italia
Tel.: 0039 02 6241121
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding public subsidies received for the development of new drugs. The decree…
Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline Therapeutics by Menarini, research collaboration between Italy and China, labelling regulations, a new biotech sector…
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics. The deal, said to…
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare diseases. We are very excited…
Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community, their core mission of translational medicine and the challenges Italy faces today with the…
The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in academic research. Division director Professor Gianvito Martino discusses the institute’s unique operative…
Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to oncology research and the institute´s significant contribution to the field in Italy. What is the…
Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute, discusses the crucial role the OBT occupies as a link between the industry…
Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies must be amenable to outside influence in order to grow sustainably. [There is] a lot of…
Thilo Stadler speaks passionately about Grünenthal’s collaborative partnerships, company goals, and workforce engagement; revealing himself to be someone who truly believes in Grünenthal’s business. You currently hold the position of…
Digitalization, a hot topic throughout the healthcare and life sciences industry, is having a major effect in Italy through more personalized home care for patients, allowing the government to cut costs,…
Regardless of external challenges, the Italian pharmaceutical industry is clearly equipped for success, in terms of physical capital, expertise, and culture. There is a “Made in Italy” element in pharmaceuticals…
See our Cookie Privacy Policy Here
